Literature DB >> 3571771

Follow-up study of 232 patients with occupational asthma caused by western red cedar (Thuja plicata).

M Chan-Yeung, L MacLean, P L Paggiaro.   

Abstract

A total of 232 patients with red cedar asthma diagnosed by inhalation provocation tests were observed an average of 4 years after the initial diagnosis. The status during the follow-up examination was as follows: 96 patients continued to work with red cedar, and 136 left the industry and had no further exposure to red cedar in their jobs or hobbies. Of the 136 patients who left the industry, only 55 (40.4%) recovered completely, whereas the remaining 81 (59.6%) continued to experience attacks of asthma of varying severity. The initial pulmonary function tests were significantly higher among the asymptomatic group compared to the symptomatic group (FEV1 99.3 +/- 2.7% versus 90.5 +/- 2.2% predicted, respectively). Methacholine PC20 during the initial examination was higher among the asymptomatic group than in the symptomatic group (1.46 +/- 3.96 mg/ml versus 0.77 +/- 4.52 mg/ml, respectively). These findings indicate that the patients in the asymptomatic group were diagnosed at an earlier stage of the disease. This observation was confirmed by the significantly shorter duration of symptoms before diagnosis among the asymptomatic patients compared to the symptomatic patients (1.6 +/- 1.9 versus 2.6 +/- 4.3 years). Race, smoking status, immediate skin reactivity, and presence of plicatic acid-specific IgE antibodies did not influence the outcome of these patients. Of the 96 patients who continued to work with red cedar, 47 were exposed daily, whereas 41 were exposed intermittently.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3571771     DOI: 10.1016/0091-6749(87)90212-0

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  16 in total

1.  Supermarket baker's asthma: how accurate is routine health surveillance?

Authors:  A Brant; S Nightingale; J Berriman; C Sharp; J Welch; A J Newman Taylor; P Cullinan
Journal:  Occup Environ Med       Date:  2005-06       Impact factor: 4.402

Review 2.  Occupational asthma. Practical points for diagnosis and management.

Authors:  W G Kuschner; R K Chitkara; P S Sarinas
Journal:  West J Med       Date:  1998-12

3.  New method for an occupational dust challenge test.

Authors:  F J Lin; H Chen; M Chan-Yeung
Journal:  Occup Environ Med       Date:  1995-01       Impact factor: 4.402

4.  Longitudinal decline in lung function in patients with occupational asthma due to western red cedar.

Authors:  F J Lin; H Dimich-Ward; M Chan-Yeung
Journal:  Occup Environ Med       Date:  1996-11       Impact factor: 4.402

Review 5.  Outcome of occupational asthma after cessation of exposure: a systematic review.

Authors:  George Rachiotis; Rashna Savani; Andrew Brant; Stephanie J MacNeill; Anthony Newman Taylor; Paul Cullinan
Journal:  Thorax       Date:  2006-10-13       Impact factor: 9.139

Review 6.  Evidence based guidelines for the prevention, identification, and management of occupational asthma.

Authors:  P J Nicholson; P Cullinan; A J Newman Taylor; P S Burge; C Boyle
Journal:  Occup Environ Med       Date:  2005-05       Impact factor: 4.402

7.  Industrial injury benefit for occupational asthma in north east of England.

Authors:  S C Stenton; P S Sandhu; D J Hendrick
Journal:  BMJ       Date:  1995-05-20

8.  Occupational asthma and extrinsic alveolitis due to isocyanates: current status and perspectives.

Authors:  O Vandenplas; J L Malo; M Saetta; C E Mapp; L M Fabbri
Journal:  Br J Ind Med       Date:  1993-03

9.  Health, employment, and financial outcomes in workers with occupational asthma.

Authors:  P F Gannon; D C Weir; A S Robertson; P S Burge
Journal:  Br J Ind Med       Date:  1993-06

10.  Occupational asthma due to soft corrosive soldering fluxes containing zinc chloride and ammonium chloride.

Authors:  D C Weir; A S Robertson; S Jones; P S Burge
Journal:  Thorax       Date:  1989-03       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.